CSIMarket
 
Vtv Therapeutics Inc   (VTVT)
Other Ticker:  
 
 
Price: $8.2150 $-0.15 -1.734%
Day's High: $8.51 Week Perf: -14.02 %
Day's Low: $ 8.10 30 Day Perf: 4.19 %
Volume (M): 6 52 Wk High: $ 39.60
Volume (M$): $ 47 52 Wk Avg: $22.09
Open: $8.47 52 Wk Low: $7.38



 Market Capitalization (Millions $) 17
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -28
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Vtv Therapeutics Inc
Vtv Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative small molecule drugs to treat various diseases. The company is known for its expertise in target-based drug discovery and employs a unique approach to drug development, utilizing cutting-edge technologies and collaborative research partnerships. Vtv Therapeutics aims to bring novel therapeutics to the market that can significantly improve patient outcomes and address unmet medical needs.


   Company Address: 3980 Premier Dr High Point 27265 NC
   Company Phone Number: 841-0300   Stock Exchange / Ticker: NASDAQ VTVT
   VTVT is expected to report next financial results on March 05, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Vtv Therapeutics Inc

Explosive Growth Unleashed: Company Surprises Shareholders with Stunning $-5.368M Rise in Latest Fiscal Period

During the past 5 trading days, Vtv Therapeutics Inc stock has experienced a significant drop of -7.33%, further contributing to a year-to-date performance decline of -51.11%. The stock is currently trading 1.1% above its 52-week low.
Vtv Therapeutics Inc operates in the Major Pharmaceutical Preparations industry, alongside larger companies in the market. While the focus is often on these major players, it is important to keep an eye on lesser-known businesses as well. VTVT, a clinical stage biopharmaceutical company specializing in the development of cadisegliatin (TTP399) as a supplementary therapy to insulin for type 1 diabetes (T1D), recently reported its earnings for the third quarter of 2023.

Shares

vTv Therapeutics Inc (Nasdaq: VTVT), a clinical stage biopharmaceutical company specializing in the development of cadisegliatin (TTP399) as a supplementary therapy to insulin for type 1 diabetes (T1D), recently announced a major milestone The company has successfully sold all of its common stock in Reneo Pharmaceuticals, Inc,

Published Wed, Nov 1 2023 12:01 PM UTC

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company specializing in the development of cadisegliatin (TTP399) as a supplementary therapy to insulin for type 1 diabetes (T1D), recently announced a major milestone. The company has successfully sold all of its common stock in Reneo Pharmaceuticals, Inc., generating an impressive $4.4 million in proc...

Vtv Therapeutics Inc

VTV Therapeutics Inc. Faces Uphill Battle: Losses Mount and Revenue Stagnates in Second Quarter of 2023

Vtv Therapeutics Inc. is a pharmaceutical company that focuses on the development of innovative therapies for the treatment of various diseases. However, their recent financial results for the period between April and June 2023 have shown an increase in losses per share compared to the previous year.
During this financial span, VTVT reported a loss per share of $-0.07, which was a significant increase from $-0.04 per share in the same period a year before. Furthermore, the loss also surged from $-0.06 per share from the prior reporting season. These numbers indicate a downward trend in the company's financial performance, suggesting that they have not been able to improve their profitability.
On the revenue front, Vtv Therapeutics Inc. did not fare any better. Their revenue remained stagnant at $0.00 million, which was the same as the corresponding reporting season a year before, and also sequentially. This lack of growth in revenue further highlights the struggles faced by the company.

Vtv Therapeutics Inc

VTVT Reports Decreases in Net Deficit but Disappoints with $-0.06 per Share Loss in Q1 2023

Vtv Therapeutics Inc is a biopharmaceutical company focused on developing innovative treatments for neurological disorders and metabolic diseases. The company's pipeline includes drug candidates for Alzheimer's disease, Parkinson's disease, type 2 diabetes, and other conditions.
The fiscal first quarter of 2023, which ended on June 30th, was a mixed period for Vtv Therapeutics Inc. On the positive side, the company managed to reduce its net deficit compared to the prior year and the prior financial period. However, Vtv Therapeutics Inc also reported a net loss of $-0.06 per share, which was worse than the consensus estimate of $-0.03 per share. The lack of revenue growth was also a disappointing factor for investors.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com